Filing Flows › ArriVent BioPharma (AVBP) › Q3 2026
ArriVent BioPharma (AVBP) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 9, 2026
ArriVent BioPharma (AVBP) reported revenue of $5.0M for the third quarter 2026 (Q3 2026). Operating margin was -867.5%, net loss $40.3M (806.3% of revenue).
ArriVent BioPharma, Q3 2026: revenue $5.0M, operating margin -867.5%, net loss $40.3M, operating cash flow −$40.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.0M | — | — |
| Operating profit | −$43.4M | — | — |
| Net earnings | −$40.3M | — | — |
| Operating cash flow | −$40.7M | — | — |
What changed
Revenue was $5.0M in Q3 2026.
Operating costs exceeded revenue by $43.4M, an operating margin of -867.5%. The quarter ended with a net loss of $40.3M.
Operating cash flow was −$40.7M. Non-cash charges added back $6.9M of share-based compensation. Working capital and other items used $7.3M.
Questions
What was ArriVent BioPharma's revenue in the third quarter 2026?
ArriVent BioPharma (AVBP) reported revenue of $5.0M for the third quarter 2026 (Q3 2026).
Was ArriVent BioPharma profitable in the third quarter 2026?
Operating loss was $43.4M (-867.5% of revenue) and net loss $40.3M.
Source: ArriVent BioPharma 10-Q on SEC EDGAR.